Probiotic Strains Inhibit Clostridium difficile Adhesion

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for Clostridium difficile infections, particularly in hospital settings, are inadequate in preventing and treating the severe symptoms and histological lesions associated with CDAD/CDI, necessitating the development of alternative therapeutic solutions that can effectively inhibit the pathogen's adhesion and proliferation in the intestinal tract.

Innovation Solution

The use of specific bacterial strains, such as Lactobacillus casei DG and Lactobacillus paracasei LPC-S01, either alone or in combination, as probiotics to inhibit Clostridium difficile adhesion and proliferation by competing with the pathogen for adhesion sites on intestinal cells, thereby reducing the severity of symptoms and lesions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional antibiotic treatments are used for Clostridium difficile infection, then the infection can be treated, but the severity of symptoms and histological lesions remains high, and recurrence is common

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidsymptom severity and lesion extent

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces probiotic bacteria (Lactobacillus casei DG and Lactobacillus paracasei LPC-S01) as intermediary substances that mediate the interaction between the host intestine and the pathogen Clostridium difficile. These probiotics compete with C. difficile for adhesion sites on intestinal cells, preventing the pathogen from causing severe symptoms and histological lesions, thereby reducing harm while maintaining treatment effectiveness

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent extracts and isolates specific probiotic strains (Lactobacillus casei DG and Lactobacillus paracasei LPC-S01) from complex microbial communities and uses them as purified therapeutic agents. This extraction allows for standardized, reliable treatment that directly targets the pathogen-adhesion mechanism, improving treatment effectiveness while reducing symptom severity

Inventive Principle:

Principle #2Taking out (Extraction)

2Adaptability or versatility

If broad-spectrum antibiotics are used to treat infections, then various types of bacteria are eliminated, but Clostridium difficile infection risk increases due to disruption of intestinal flora

Engineering Contradiction:

Improveantibiotic coverageVSAvoidC. difficile infection risk

Core Design Contradiction:

Adaptability or versatilityVSObject-affected harmful factors

Solution Approach 1:

The patent converts the harmful effect of antibiotic-induced intestinal flora disruption into a beneficial opportunity for probiotic intervention. By introducing Lactobacillus casei DG and Lactobacillus paracasei LPC-S01, the treatment exploits the disrupted ecological niche to establish protective bacterial communities that prevent C. difficile infection, turning the harmful antibiotic side effect into a beneficial probiotic establishment window

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent changes the microbial composition parameter of the intestinal flora by introducing specific probiotic strains. This parameter change shifts the microbial ecosystem from a state vulnerable to C. difficile infection (after broad-spectrum antibiotic use) to a protective state where the probiotics compete with and inhibit the pathogen, reducing infection risk while maintaining antibiotic coverage versatility

Inventive Principle:

Principle #35Parameter changes

3Reliability

If probiotics are used to inhibit Clostridium difficult adhesion, then pathogen adhesion is reduced, but the mechanism of action is not fully understood

Engineering Contradiction:

Improveadhesion inhibitionVSAvoidmechanism of action knowledge

Core Design Contradiction:

ReliabilityVSLoss of information

Solution Approach 1:

The patent performs preliminary characterization and identification of the probiotic strains (Lactobacillus casei DG and Lactobacillus paracasei LPC-S01) before using them in treatment. By preliminarily establishing their adhesion inhibition capability and safety profile, the patent enables reliable clinical application while the full mechanism of action is systematically investigated through the provided experimental data

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The described probiotic strains demonstrate significant inhibition of Clostridium difficile adhesion and proliferation, with Lactobacillus paracasei LPC-S01 showing a 75% reduction in adhesion, effectively alleviating symptoms and lesions associated with CDAD/CDI, and the combination of strains exhibiting a synergistic effect in reducing pathogen adhesion.

Implementation Method 1

The use of specific bacterial strains, such as Lactobacillus casei DG and Lactobacillus paracasei LPC-S01, either alone or in combination, as probiotics to inhibit Clostridium difficult adhesion and proliferation by competing with the pathogen for adhesion sites on intestinal cells

Methodology Applied

Scientific EffectCompetitive inhibition:

Data Source

PatentEP3681470B1Lactobacillus casei or lactobacillus paracasei for use in the treatment of clostridium difficile infections

Publication Date: 2023.11.08 LAC2BIOME SRL

Figure 1A~1B
Figure 2A~2C
Figure 3

AI summary

The present invention relates to the use of specific strains of Lactobacillus paracasei or of a composition comprising said strains for the prevention and/or treatment of a physiopathological condition related to/associated with Clostridium difficile infection, preferably intestinal infections, or so-called CD-associated disease (CDAD) or CD infection (CDI).